Phase I / II clinical trial of peptide vaccination therapy for unresectable / recurrent pancreatic cancer to be refractory to chemotherapy by using new tumor antigen KIF20A and A2402 restrictive epitope peptide of the VEGFR1 origin related gene of tumor vascularization

UMIN ID: UMIN000002022

Registered date:31/05/2009

Basic Information

• Recruitment status: Complete: follow-up complete
• Health condition(s) or Problem(s) studied: pancreatic cancer
• Date of first enrollment: 2009/05/01
• Target sample size: 36
• Countries of recruitment: Japan
• Study type: Interventional
• Intervention(s): Cancer vaccination therapy by using new tumor antigen KIF20A and A2402 restrictive epitope peptide of the VEGFR1 origin related gene of tumor vascularization against patients who have unresectable / recurrent pancreatic cancer to be refractory to chemotherapy.

Outcome(s)

• Primary Outcome: safety
• Secondary Outcome: immunologicaresponse and clinocal efficacy

Key inclusion & exclusion criteria

• Age minimum: 20years-old
• Age maximum: 85years-old
• Gender: Male and Female
• Exclude criteria: 1. Patients have uncontrollable associated cancer. 2. Patients have uncontrollable severe infectional diseases. 3. Patients have severe trauma. 4. Patients who are treated with steroid or immunotherapy during clinical trial. 5. Pregnancy or lactation. 6. Patients who have non-recovered injury. 7. Patients judged inappropriated by doctors.

Related Information

• Primary Sponsor: Department of Gastroenterology, Juntendo University School of Medicine
• Source(s) of Monetary Support: Juntendo University School of Medicine